Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07186660 · ClinicalTrials.gov registry record · Phase 2

Evaluation of a Novel Insulin Sensitizer in People With Type 1 Diabetes

A Phase 2 study of Type 1 Diabetes (T1D) and Cardiovascular Health, sponsored by University of Virginia.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT07186660 is a Phase 2 study of Type 1 Diabetes (T1D) and Cardiovascular Health that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 40 participants, below the 178-participant average among 17 other Type 1 Diabetes (T1D) trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07186660, a Phase 2 study of Type 1 Diabetes (T1D) and Cardiovascular Health, is actively recruiting participants, sponsored by University of Virginia.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to see if the study drug CIR-0602K will improve glucose time-in-range and/or lower total daily insulin dose in people with type 1 diabetes who are using closed-loop automated insulin delivery. Researchers will compare CIR-0602K to a placebo (a look-alike substance that contains no drug) to see if it achieves the investigational endpoints. If the study results show that the drug works to increase time-in-range and lower insulin doses, this will lead to further studies which may then make the drug available to the public.

Conditions Studied

Type 1 Diabetes (T1D) Cardiovascular Health Insulin Glycemic Control for Diabetes Mellitus Ketones

Interventions

  • DRUG Placebo
  • DRUG CIR-0602K

Study Locations (1)

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2026-02-22
Est. Completion 2028-09
Phase Phase 2

Sponsor

University of Virginia

449 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07186660

The ClinicalTrials.gov registry entry for NCT07186660 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 17 other Type 1 Diabetes (T1D) trials with a reported enrollment target (78% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Type 1 Diabetes (T1D) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07186660 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT07186660 about?

NCT07186660 is a clinical study titled "Evaluation of a Novel Insulin Sensitizer in People With Type 1 Diabetes". The purpose of this study is to see if the study drug CIR-0602K will improve glucose time-in-range and/or lower total daily insulin dose in people with type 1 diabetes who are using closed-loop automated insulin delivery. Researchers will compare CIR-0602K to a placebo (a look-alike substance that c...

What is the current status of trial NCT07186660?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2026-02-22. Estimated completion is 2028-09.

What conditions does trial NCT07186660 study?

This clinical trial studies the following conditions: Type 1 Diabetes (T1D), Cardiovascular Health, Insulin, Glycemic Control for Diabetes Mellitus, Ketones.

What interventions are being tested in trial NCT07186660?

The interventions under investigation include: Placebo (DRUG), CIR-0602K (DRUG).

Who is sponsoring clinical trial NCT07186660?

This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07186660 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 1 Diabetes (T1D)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 1 Diabetes (T1D)

All registered trials for this condition

Cardiovascular Health

All registered trials for this condition

Virginia

All trials with a study site in Virginia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.